Clinical trials: Prevention of Ischemic Stroke
Socioeconomic Status, Secondary Prevention
Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction
This is a nationwide cohort study on real-world patients (n≈30,000) surviving a first myocardial infarction (MI) 2006-2013 and alive to attend a routine 1-year follow-up.
- Conditions
- Socioeconomic Status, Secondary Prevention, Myocardial Infarction, Cardiovascular Disease
- Trial name
- NCT04199663
- Volunteers
- 30,191 people
- Sponsor
- Karolinska Institutet
Embolic Stroke of Undetermined Source
Embolic Stroke of Undetermined Source, Continuous Electrocardiography and Transthoracic ECHOcardiography in Hospitalized Patients With Ischemic Stroke
Transthoracic echocardiography (TTE) is recommended in patients with ischemic stroke when cardiac etiology is suspected to help plan secondary stroke management.
- Trial name
- ESECHO (NCT04808258)
- Testing
- C3+ Holter Monitor
- Where
- 2 sites in Denmark
- Volunteers
- 500 people
- Sponsor
- Herlev and Gentofte Hospital
Stroke, Transient Ischemic Attack
China Stroke Secondary Prevention Trial
The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary stroke prevention trial in China to determine whether the addition of folic acid and vitamin supplements will reduce recurrent stroke…
- Trial name
- CSSPT (NCT01317849)
- Testing
- Folic Acid, Vitamin B6, Vitamin B12
- Where
- China
- Sponsor
- Xijing Hospital
Stroke
The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule
In order to observe the secondary preventive effect of the Dengzhanshengmai capsule on ischemic stroke, the investigators hold the large randomized control trial (RCT).
- Trial name
- SPIRITDZSM1 (NCT00548223)
- Testing
- Dengzhan Shengmai capsule
- Where
- 84 sites in China
- Volunteers
- 3,143 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Hyperlipidemia
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.
- Trial name
- NCT00211705
- Testing
- Diet, Diet+pravastatin
- Volunteers
- 8,000 people
- Sponsor
- Mitsukoshi Health and Welfare Foundation
Thrombotic Stroke, Atrial Fibrillation and Flutter
ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)
The aim of this study is to evaluate the present status of stroke prevention strategies in patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- RAMSES (NCT02344901)
- Where
- 62 sites in Turkey (Türkiye)
- Volunteers
- 6,273 people
- Sponsor
- Muğla Sıtkı Koçman University
Brain Infarction, Transient Ischemic Attack
Aortic Arch Related Cerebral Hazard Trial (ARCH)
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology.
- Conditions
- Brain Infarction, Transient Ischemic Attack, Embolism
- Trial name
- ARCH (NCT00235248)
- Testing
- Warfarin, Clopidogrel-aspirin
- Where
- 2 sites in Australia, France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stroke
Addiction & Stroke
Modifiable stroke risk-factors, which include poor lifestyle habits, account for 90 % of the risk of stroke. Disability Adjusted Life Years (DALYs) related to cerebrovascular disorders rely on three main factors, including the…
- Trial name
- ADDICT-STROKE (NCT06187025)
- Testing
- Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), Ecological Momentary Assessment (EMA)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Bordeaux
Ischemic Attack, Transient, Stroke
Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke
This study evaluates the use of Colchicine in adults over 40 years of age who have suffered an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other defined causes.
- Trial name
- CONVINCE (NCT02898610)
- Testing
- Colchicine
- Where
- 145 sites in Belgium, Canada and 12 more
- Volunteers
- 3,154 people
- Sponsor
- University College Dublin
Ischemic Stroke, Blood Pressure
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients
Elevated blood pressure (BP) consists of a major public health concern especially in low and middle income countries. Besides being a highly prevalent condition, it is also a risk factor for several major cardiovascular events…
- Conditions
- Ischemic Stroke, Blood Pressure, Cognitive Impairment, Vascular Diseases
- Trial name
- OPTIMAL Stroke (NCT04036409)
- Testing
- Intensive Control of Systolic Blood Pressure (SBP), Standard control of Systolic Blood Pressure (SBP)
- Where
- 30 sites in Brazil
- Volunteers
- 4,368 people
- Sponsor
- Hospital Israelita Albert Einstein
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Stroke, Coronary Artery Disease
Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
There are many reports about the association of coronary artery disease (CAD) and cerebral artery stenosis (CAS), which had been proved to induce stroke and cognition decline after the revascularization including coronary bypass…
- Conditions
- Stroke, Coronary Artery Disease, Arrhythmia
- Trial name
- NCT00247533
- Testing
- Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Far Eastern Memorial Hospital
Cerebral Infarction
Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke
The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003. From the end of May 2004 to the end of Dec.
- Trial name
- NCT00202020
- Testing
- Cilostazol 200mg/day Oral, Aspirin 100mg/day Oral
- Where
- 12 sites in China
- Volunteers
- 720 people
- Sponsor
- Otsuka Beijing Research Institute
Carotid Artery Disease, Carotid Stenosis
Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)
To collect clinical outcome and device performance data on the FDA 510(k)-cleared Emboshield® BareWire™ Rapid Exchange Embolic Protection System and FDA-approved Xact® Rapid Exchange Carotid Stent System when used under…
- Conditions
- Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
- Trial name
- NCT00287508
- Testing
- Carotid artery stenting with filter (interventional)
- Volunteers
- 1,500 people
- Sponsor
- Abbott Medical Devices
Acute Ischemic Stroke
Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke
The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.
- Trial name
- QUIET (NCT06857487)
- Testing
- Qingre Huatan Formula, Guidelines-based standard care
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Dongzhimen Hospital, Beijing
Cardiovascular Diseases, Myocardial Infarction
Real World Evidence Study of Statin Use in Brazil
A cross-sectional real-world data study designed to assess the use of statins in individuals assisted within the primary care system in Brazil.
- Conditions
- Cardiovascular Diseases, Myocardial Infarction, Stroke, Hypertension
- Trial name
- RWE-Statins (NCT05285085)
- Testing
- Statin
- Where
- Brazil
- Volunteers
- 2,133,900 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer